TORONTO, Sept. 18, 2014 /CNW/ - Microbix Biosystems Inc.
(TSX: MBX), an innovator and manufacturer of biological products
and technologies, has been named a finalist for the prestigious
Ontario Business Achievement Award (OBAA) sponsored by the
Ontario Chamber of Commerce in the
Ontario Going Global medium-sized business category.
This award honours companies in Canada's most populous province with 50-500
employees that have increased exports by 20% or more in one year.
This year, Microbix is one of two finalists selected from over 100
businesses considered for the Ontario Going Global
award.
"I believe Microbix exemplifies Ontario's ideal of a fast growing mid-sized
company," says Vaughn
Embro-Pantalony, President and CEO of Microbix. "Consider
that we are a high-tech life sciences company; we employ a diverse
and highly skilled team of scientists and technologists; we have
expanded our workforce nearly 50% in the last 12 months; we are
developing innovative products including our new dengue fever
antigens and molecular diagnostics products; and we have grown our
export sales more than 35% in the past year."
The Ontario Chamber of
Commerce, host of the "OBAAs", will announce the Ontario Going
Global winners at a gala event in Toronto in November.
"Being recognized by the Ontario Chamber of Commerce for our success is
an important endorsement of our recent accomplishments at
Microbix." says Mr. Embro-Pantalony.
The OBAAs have been honouring Ontario's most successful businesses and
celebrating their impact on the provincial economy annually for 32
years. This year again they will recognize the integrity, hard
work, innovation, entrepreneurship, and export excellence that goes
into making good companies great. The 2014 OBAAs gala runs
from 6:00 to 9:30 p.m. on
Wednesday, November 26 at the Metro
Toronto Convention Centre. To reserve tickets [explain how or
provide a link].
About Microbix Biosystems Inc.
Microbix Biosystems Inc. specializes in the research and
development of biological solutions, including products for human
health applications, namely in the vaccine, therapeutic and
diagnostic markets, as well as animal reproductive markets
worldwide. The Company manufactures and distributes a wide range of
infectious disease antigens to a worldwide customer base. The
Company's pipeline of innovative technologies and products includes
LumiSort™ semen sexing technology for the livestock industries,
Kinlytic®, a thrombolytic drug with several approved and potential
applications including the treatment of life-threatening blood
clots, and VIRUSMAX®, a proprietary technology for increasing virus
yields in the manufacture of influenza vaccine. Established in
1988, Microbix is a publicly traded company, listed on the Toronto
Stock Exchange, and headquartered in Mississauga, Ontario.
Disclaimer
This press release may contain forward-looking statements which
are subject to risks and uncertainties that could cause actual
results to differ materially from those set forth in the
forward-looking statements. These forward-looking statements
represent the Company's judgment as of the date of this press
release. The Company disclaims any intent or obligation to update
these forward-looking statements
SOURCE Microbix Biosystems Inc.
